South Korea Vaccine Market PPT 2024: Size, Growth, Demand and Forecast till 2032
                     South Korea Vaccine 
Market Research and 
Forecast Report 2024-
2032
Format: PDF+EXCEL
© 2023 IMARC All Rights Reserved 
About IMARC Group
IMARC Group is  a g lobal  management  consul t ing f i rm that  he lps the wor ld ’s  most  ambi t ious 
changemakers  to create a las t ing impact .  Across the s ix  major  cont inents  and 100+ count r ies ,  we 
work a longside our  bus iness par tners  as one team wi th  a common ambi t ion to achieve unparal le led 
resul ts ,  gain a compet i t ive edge,  and t ransform indust r ies .  IMARC Group excels  in  unders tanding 
i ts  c l ients ’  bus iness pr ior i t ies  and del iver ing ta i lored solut ions that  dr ive meaningfu l  outcomes.  Our 
c l ient  base spans over  3,000 organizat ions in  the pr ivate,  publ ic ,  and soc ia l  sectors ,  ranging f rom 
high-growth s tar tups to For tune 500 companies.
We prov ide a comprehensive sui te of  market  entry  and expansion serv ices.  Our of fer ings inc lude 
thorough market  assessment ,  feas ib i l i ty  s tudies,  company incorporat ion ass is tance,  fac tory  setup 
suppor t ,  regulatory  approvals and l icens ing navigat ion,  branding,  market ing and sales st rategies,  
compet i t ive landscape and benchmark ing analyses,  pr ic ing and cost  research,  and procurement  
research.  These serv ices are des igned to ass is t  companies in  evaluat ing market  oppor tuni t ies ,  
set t ing up new ent i t ies ,  navigat ing regulatory landscapes,  boost ing brand v is ib i l i ty ,  analyz ing 
compet i tors,  and opt imiz ing procurement  s t rategies.
A c c o r d i n g  t o  t h e  l a t e s t  r e p o r t  b y  I M A R C  G r o u p ,  t i t l e d  " S o u t h  K o r e a  V a c c i n e  M a r k e t :  
I n d u s t r y  T r e n d s ,  S h a r e ,  S i z e ,  G r o w t h ,  O p p o r t u n i t y  a n d  F o r e c a s t  2 0 2 4 - 2 0 3 2 , "  t h e  S o u t h  
K o r e a  v a c c i n e  m a r k e t  s i z e  i s  p r o j e c t e d  t o  e x h i b i t  a  g r o w t h  r a t e  ( C A G R )  o f  4 . 1 4 %  d u r i n g  2 0 2 4 -
2 0 3 2 .
T h e  p r o a c t i v e  s t a n c e  o f  t h e  g o v e r n i n g  b o d y  i n  s u p p o r t i n g  t h e  b i o t e c h n o l o g y  a n d  
Report p h a r m a c e u t i c a l  s e c t o r s  i s  p r o p e l l i n g  t h e  m a r k e t  g r o w t h  i n  S o u t h  K o r e a .  T h i s  i s  l e a d i n g  t o  h i g h e r  f u n d i n g  f o r  v a c c i n e  r e s e a r c h  a n d  d e v e l o p m e n t  ( R & D ) ,  w h i c h  i s  e n c o u r a g i n g  i n n o v a t i o n  
a n d  t h e  d e v e l o p m e n t  o f  n e w  a n d  m o r e  e f f e c t i v e  v a c c i n e s .  T h e  c o m m i t m e n t  o f  t h e  g o v e r n i n g  
Highlight and b o d y  i n  t h i s  s e c t o r  i s  a l s o  r e f l e c t e d  i n  t h e  e s t a b l i s h m e n t  o f  p u b l i c - p r i v a t e  p a r t n e r s h i p s  ( P P P )  a i m e d  a t  a c c e l e r a t i n g  v a c c i n e  d e v e l o p m e n t  a n d  p r o d u c t i o n .  M o r e o v e r ,  t h e  g r o w i n g  a w a r e n e s s  
a b o u t  t h e  i m p o r t a n c e  o f  v a c c i n a t i o n  a m o n g  t h e  p o p u l a t i o n  t h r o u g h  p u b l i c  h e a l t h  c a m p a i g n s  
Description a n d  e d u c a t i o n a l  i n i t i a t i v e s  i s  o f f e r i n g  a  f a v o r a b l e  m a r k e t  o u t l o o k .  T h i s  i s  l e a d i n g  t o  h i g h e r  v a c c i n a t i o n  r a t e s  a c r o s s  a l l  a g e  g r o u p s ,  c o n t r i b u t i n g  t o  t h e  o v e r a l l  d e m a n d  f o r  v a c c i n e s .  
A d d i t i o n a l l y ,  t h e  r i s i n g  a g i n g  p o p u l a t i o n  i n  t h e  c o u n t r y  i s  l e a d i n g  t o  t h e  d e v e l o p m e n t  o f  
v a c c i n e s  f o r  o l d e r  a d u l t s ,  s u c h  a s  t h o s e  f o r  i n f l u e n z a  a n d  p n e u m o n i a ,  w h i c h  a r e  c r u c i a l  f o r  
p r o t e c t i n g  v u l n e r a b l e  p o p u l a t i o n s .  T h e  d e m o g r a p h i c  s h i f t  t o w a r d s  a n  o l d e r  p o p u l a t i o n  i s  
c a t a l y z i n g  t h e  d e m a n d  f o r  v a c c i n e s  s p e c i f i c a l l y  t a r g e t e d  a t  a g e - r e l a t e d  d i s e a s e s .
R e q u e s t  f o r  a  P D F  s a m p l e  o f  t h i s  r e p o r t :  
h t t p s : / / w w w . i m a r c g r o u p . c o m / s o u t h - k o r e a - v a c c i n e - m a r k e t / r e q u e s t s a m p l e
Report Description
South Korea  Vacc ine  Market  T rends :
Apar t  f rom th is ,  t he  adop t ion  o f  new techno log ies ,  inc lud ing  messenger  r ibonuc le ic  ac id  (mRNA)  vacc ines  and  
recomb inan t  p ro te in  vacc ines ,  i s  enab l ing  the  p roduc t ion  o f  more  e f fec t i ve  and  sa fe r  vacc ines .  These  
advancements  a re  no t  on ly  imp rov ing  the  e f f i cacy  o f  vacc ines  bu t  a re  a l so  reduc ing  the  t ime  requ i red  fo r  the i r  
deve lopment  and  p roduc t ion .  The  in teg ra t ion  o f  cu t t ing -edge  techno log ies  in to  the  vacc ine  p roduc t ion  p rocess  i s  
enhanc ing  the  ab i l i t y  o f  t he  coun t ry  to  respond  swi f t l y  to  emerg ing  in fec t ious  d i seases .  
Fur the rmore ,  the  inc reas ing  focus  on  persona l i zed  med ic ine ,  wh ich  i s  ta i l o red  to  the  gene t ic  makeup  o f  
ind iv idua ls ,  i s  ga in ing  t rac t ion  as  a  p romis ing  app roach  to  improv ing  vacc ine  e f f i cacy .  Bes ides  th i s ,  the  
improvement  o f  co ld  cha in  log is t i cs  and  d is t r i bu t ion  in f ras t ruc tu re  is  ensur ing  tha t  vacc ines reach  even  the  mos t  
remote  a reas  o f  the  coun t ry .  Th is  i s  pa r t i cu la r ly  impo r tan t  f o r  ma in ta in ing  the  e f f i cacy  o f  vacc ines ,  as  many  
requ i re  spec i f i c  s to rage  cond i t ions .  The  enhancement  o f  d is t r ibu t ion  ne two rks  i s  a lso  enab l ing  fas te r  and  more  
e f f i c ien t  de l i ve ry  o f  vacc ines ,  wh ich  i s  c ruc ia l  in  respond ing  to  pub l ic  hea l th  emergenc ies .
View Repor t  TOC,  F igures  and  Tables :  h t tps: / /www. imarcgroup.com/south-korea-vacc ine-market
Product Type Insights:
• Multivalent Vaccine
• Monovalent Vaccine
 
Treatment Type Insights:
• Preventive Vaccine
• Therapeutic Vaccine
Report 
Segmentation Technology Insights:
• Conjugate Vaccines
• Inact ivated and Subunit  Vaccines
• Live Attenuated Vaccines
• Recombinant Vaccines
• Toxoid Vaccines
• Others
Route of Administration Insights:
• Intramuscular and Subcutaneous 
Administration
• Oral  Administration
• Others
 
Patient Type Insights:
Report • Pediatr ic
Segmentation • Adult
Indication Insights:
• Bacterial  Diseases
o Meningococcal  Disease
o Pneumococcal  Disease
o Diphtheria/Tetanus/Pertussis (DPT)
o Tuberculosis
o Haemophi lus Infl uenzae (Hib)
o Typhoid
o Others
• Viral  Diseases
o Hepatit is
o Infl uenza
Report o Human Papi l lomavirus (HPV)
Segmentation o Measles/Mumps/Rubel la (MMR)
o Rotavirus
o Herpes Zoster
o Varicel la
o Japanese Encephal i t is
o Rubel la
o Pol io
o Rabies
o Dengue
o Others
Distribution Channel Insights:
• Hospital  Pharmacies
Report • Retai l  Pharmacies
Segmentation • Insti tut ional  Sales
• Others
End User Insights:
• Hospitals
• Clinics
• Vaccinat ion Centers
• Academic and Research Insti tutes
• Others
Regional Insights:
• Seoul Capital  Area
• Yeongnam (Southeastern Region)
Report • Honam (Southwestern Region)
Segmentation • Hoseo (Central  Region)
• Others
How has the South Korea vaccine market performed so 
far and how will it perform in the coming years?
What has been the impact of COVID-19 on the South 
Korea vaccine market?
What is the breakup of the South Korea vaccine market 
Key on the basis of product type?
Questions What is the breakup of the South Korea vaccine market on the basis of treatment type?
Answered in 
What is the breakup of the South Korea vaccine market 
the Report on the basis of technology?
What is the breakup of the South Korea vaccine market 
on the basis of route of administration?
What is the breakup of the South Korea vaccine market 
on the basis of patient type?
What is the breakup of the South Korea vaccine market 
on the basis of indication?
What is the breakup of the South Korea vaccine market 
on the basis of distribution channel?
What is the breakup of the South Korea vaccine market 
on the basis of end user?
Key What are the various stages in the value chain of the South Korea vaccine market? 
Questions 
What are the key driving factors and challenges in the 
Answered in South Korea vaccine?
the Report What is the structure of the South Korea vaccine market 
and who are the key players?
What is the degree of competition in the South Korea 
vaccine market?
1     P r e f a c e
2     S c o p e  a n d  M e t h o d o l o g y
    2 . 1     O b j e c t i v e s  o f  t h e  S t u d y
    2 . 2     S t a k e h o l d e r s
    2 . 3     D a t a  S o u r c e s
        2 . 3 . 1     P r i m a r y  S o u r c e s
        2 . 3 . 2     S e c o n d a r y  S o u r c e s
    2 . 4     M a r k e t  E s t i m a t i o n
Table of         2 . 4 . 1     B o t t o m - U p  A p p r o a c h        2 . 4 . 2     T o p - D o w n  A p p r o a c h
    2 . 5     F o r e c a s t i n g  M e t h o d o l o g y
3     E x e c u t i v e  S u m m a r y
4    S o u t h  K o r e a  V a c c i n e  M a r k e t  -  I n t r o d u c t i o n
Contents     4 . 1     O v e r v i e w    4 . 2     M a r k e t  D y n a m i c s
    4 . 3     I n d u s t r y  T r e n d s
    4 . 4     C o m p e t i t i v e  I n t e l l i g e n c e
5    S o u t h  K o r e a  V a c c i n e  M a r k e t  L a n d s c a p e
    5 . 1     H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
    5 . 2     M a r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )
6    S o u t h  K o r e a  V a c c i n e  M a r k e t  -  B r e a k u p  b y  P r o d u c t  T y p e
    6 . 1     M u l t i v a l e n t  V a c c i n e
        6 . 1 . 1  O v e r v i e w
        6 . 1 . 2  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
        6 . 1 . 3  M a r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )
    6 . 2     M o n o v a l e n t  V a c c i n e
        6 . 2 . 1  O v e r v i e w
        6 . 2 . 2  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
        6 . 2 . 3  M a r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )
       
7    S o u t h  K o r e a  V a c c i n e  M a r k e t  -  B r e a k u p  b y  T r e a t m e n t  T y p e
    7 . 1     P r e v e n t i v e  V a c c i n e
        7 . 1 . 1  O v e r v i e w
        7 . 1 . 2  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
        7 . 1 . 3  M a r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )
    7 . 2     T h e r a p e u t i c  V a c c i n e
        7 . 2 . 1  O v e r v i e w
        7 . 2 . 2  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
        7 . 2 . 3  M a r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )
8    S o u t h  K o r e a  V a c c i n e  M a r k e t  -  B r e a k u p  b y  T e c h n o lo g y
Table of     8 . 1     C o n j u g a t e  V a c c i n e s
        8 . 1 . 1  O v e r v i e w
        8 . 1 . 2  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
Contents         8 . 1 . 3  M a r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )    8 . 2     I n a c t i v a t e d  a n d  S u b u n i t  V a c c i n e s
        8 . 2 . 1  O v e r v i e w
        8 . 2 . 2  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
        8 . 2 . 3  M a r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )
    8 . 3     L i v e  A t t e n u a te d  V a c c i n e s
        8 . 3 . 1  O v e r v i e w
        8 . 3 . 2  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
        8 . 3 . 3  M a r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )
    8 . 4     R e c o m b i n a n t  V a c c i n e s
        8 . 4 . 1  O v e r v i e w
        8 . 4 . 2  H i s t o r i c a l  a n d  C u r r e n t  M a r k e t  T r e n d s  ( 2 0 1 8 - 2 0 2 3 )
        8 . 4 . 3  M a r k e t  F o r e c a s t  ( 2 0 2 4 - 2 0 3 2 )     
F o r  m o r e  i n f o r m a t io n ,  v i s i t :  
ht tps : / /www. imarcgroup .com/south -korea-vacc ine -marke t / to
c
Partial List of Clients
Partial List of Clients
Disclaimer
© 2024  IMARC Al l  R ights  Reserved 
Th is  Pub l i ca t ion  and  a l l  i t ’ s  con ten ts  un less  o therw ise  men t i oned  a re  copy r i gh ted  in  the  name o f  
I n t e rna t i ona l  Marke t  Ana lys i s  Research  and  Consu l t ing  ( IMARC) .  No  pa r t  o f  t h i s  pub l i ca t ion  may  be  
rep roduced ,  repackaged ,  red i s t r i bu ted  o r  res o ld  i n  who le  o r  i n  any  pa r t .  The  pub l i ca t ion  may  a l so  
no t  be  used  i n  any  f o rm o r  by  and means  g raph i c  e lec t ron ic  o r  mechan ic a l ,  i nc lud ing  pho tocopy ing ,  
reco rd ing ,  t ap ing  o r  by  i n fo rmat i on  s to rage  o r  re t r ieva l ,  o r  by  any  o the r  f o rm,  w i t hou t  the  exp ress  
c ons en t  o f  I n t e rna t iona l  Marke t  Ana lys i s  Research  and  Consu l t i ng  ( IMARC) .
Disc la imer :  Al l  con ten ts  and  da ta  o f  t h i s  pub l i c a t i on ,  i nc lud ing  fo recas t s ,  da ta  ana lys i s  and  op in ion  
have  been  based  on  in f o rmat ion  and  sources  be l ieved  to  be  accu ra te  and  re l iab le  a t  t he  t ime  o f  
pub l i sh ing .  In t e rna t i ona l  Ma rke t  Ana l ys is  Research  and  Consu l t ing  makes  no  rep resen ta t ion  o f  
war ran t y  o f  any  k ind  as  to  t he  acc u racy  o r  comp le teness  o f  any  I n fo rmat i on  p rov ided .  IMARC 
accep ts  no  l i ab i l i t y  wha tsoever  f o r  any  los s  o r  damage  resu l t i ng  f rom op in ion ,  e r ro rs  o r  
i naccu rac ies  i f  any  f ound  th is  pub l i ca t ion .
IMARC,  IMARC Group  and  G loba l  Therapy  I ns igh t  Ser i es  a re  reg is t e red  t rademarks  o f  I n te rna t iona l  
Marke t  Ana lys i s  Research  and  Consu l t ing .  A l l  o the r  t rademarks  used  i n  th i s  pub l i ca t i on  a re  
reg i s te red  t rademarks  o f  t he i r  r espec t i ve  compan ies .
Contact Us
Visit us at :
https://www.imarcgroup.com
+1-631-791-1145
[email protected]
Stay With Us: